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Abstract 
Objective: To determine the occurrence and severity of oral mucositis (OM) and the factors associated with 
the onset of severe oral mucositis (SOM) in pediatric cancer patients. Material and Methods: This was a 
longitudinal and prospective study with 85 children and adolescents (aged 0 to 19 years) admitted to the 
Pediatric Oncology Sector of Napoleão Laureano Hospital between November 2016 and July 2019. The 
patients’ sociodemographic and epidemiological information, as well as hematological and biochemical 
parameters, were obtained from their medical charts. The oral mucosa of study participants was assessed 
through the modified Oral Assessment Guide (OAG) at baseline and after the 2nd, 5th and 10th week of 
antineoplastic treatment. Data were analyzed by Chi-square test to determine the factors associated with 
the occurrence of SOM (p<0.05). Results: The occurrence of OM was more frequent in the 2nd (60%), 5th 
(40.9%) and 10th week (43.2%) of antineoplastic treatment. During the follow-up period, SOM was more 
frequent in the 5th week (34.7%), followed by the 2nd (32.3%) and 10th weeks (29.7%). There was no 
association between the occurrence of SOM and the patient's age, type of tumor, chemotherapy regimen, 
and hematological and biochemical parameters. Conclusion: The occurrence of oral mucositis in pediatric 
cancer patients was significant, especially in the 2nd week of antineoplastic treatment. Severe oral mucositis 
was more prevalent in the 5th week of treatment and was not associated with any of the study variables. 
 
Keywords: Oncology Service, Hospital; Pediatrics; Mucositis; Oral Health.
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Introduction 
In Brazil, cancer is the leading cause of death from illness among children and adolescents aged 1 to 
19 years. Leukemias, tumors of the central nervous system (CNS) and lymphomas are among the most incident 
neoplasms in childhood [1,2]. While the antineoplastic treatment has been consistently optimized, drug-
related complications may still occur, including mucositis, xerostomia, dysfunction of the salivary glands, and 
fungal or viral infections [3,4]. The high incidence of oral manifestations resulting from the antineoplastic 
treatment can be explained by the fact that chemotherapy, the treatment of choice for childhood cancer, 
primarily affects sites with high cell turnover, such as the oral mucosa of younger patients [5]. 
The onset and progression of oral mucositis (OM) depends considerably on several factors related to 
both the antineoplastic treatment and the patient's characteristics and individual susceptibility. Some of the 
treatment-related variables that can affect the prevalence and severity of mucositis are the drug type, dose and 
schedule of administration; the radiation field size and dose; and the concomitant exposure to chemotherapy 
and radiotherapy. Among the patient-related factors are age, body mass index, sex, hematological and 
biochemical alterations, changes in salivary production, poor oral health, and trauma to the mucosa [6,7]. 
Different scales have been proposed to diagnose OM and to assess its severity in children; for instance, 
the modified Oral Assessment Guide (OAG) [7,8]. The modified OAG serves not only to screen for 
disruptions in the integrity of the oral mucosa, but it also allows for early identification of oral conditions, 
rendering therapeutic interventions timely and more clinically effective. This is critical to prevent OM from 
evolving to a more severe degree, in which patients can experience more intense painful symptoms and 
difficulties in speech, swallowing, chewing and, ultimately, in nourishing [3,9]. Accordingly, severe oral 
mucositis (SOM) may negatively impact the quality of life of children and adolescents and lead them to 
interrupt chemotherapy or radiotherapy, which considerably increases their risk of death [10]. 
The healthcare team should be aware of the specific moment during the antineoplastic treatment when 
SOM is more likely to develop, in order to optimize the therapeutic intervention and to improve the patient’s 
quality of life [11]. Thus, in this study, we determined the occurrence of oral mucositis (OM) and severe oral 
mucositis (SOM) in pediatric cancer patients undergoing antineoplastic treatment, and we further identified the 
factors associated with the onset of SOM. 
 
Material and Methods 
Study Design and Sample Characteristics 
This was a longitudinal, prospective, observational study with a quantitative approach. The study 
location was the Pediatric Oncology Sector of Napoleão Laureano Hospital (HNL, in Portuguese), located in 
the city of João Pessoa, Paraíba State, northeastern Brazil. The state of Paraíba has an estimated population of 
3,766,528 inhabitants, of which 1,305,858 are aged between 0 and 10 years [12]. HNL is a state-wide reference 
center for cancer treatment, providing more than 40 thousand monthly consultations, exams, and surgeries 
[13]. 
The following eligibility criteria were considered: patients aged 0 to 19 years, of both sexes, 
undergoing antineoplastic treatment at HNL from November 2016 to July 2019, enrolled in the Brazilian 
Healthcare System, and that consented to participate in the study. At baseline (at diagnosis or prior to the start 
of treatment), the sample comprised a total of 85 patients. During follow-up, there were sample dropouts due 
to the transfer of patients to continue treatment in other locations (n = 17), home stay (n = 20), or due to death 
(n = 11). Sixty-eight participants were assessed in the 2nd week, then 49 in 5th week and 37 in 10th week. 
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Data Collection 
The following information was obtained the patients’ medical charts: sociodemographic status and 
epidemiological information (sex, age, skin color and city of residence); data related to the underlying disease, 
type of antineoplastic treatment, time since the last treatment (chemotherapy and / or radiotherapy), class and 
type of chemotherapeutic drug, leukocyte and platelet count, and blood creatinine level. 
The oral mucosa of study participants was assessed through the modified Oral Assessment Guide 
(OAG) [14,15]. This is a simple, easy-to-apply tool that was specifically designed to assess OM in children and 
that requires only 3 to 4 minutes to be completed [16]. The OAG includes eight items (voice, swallowing, lips, 
tongue, saliva, jugal / palate mucosa, labial mucosa, and gingiva), which are assessed based on an oral health 
impairment scale. Each item was assigned a score ranging from 1 to 3, as follows: 1 - Normal condition; 2 - 
Mild to moderate alteration in the integrity of the oral epithelium or functional alterations; 3 - Severe 
impairment. The total score could range from 8 to 24, with no cutoff point. In our study, a score of 3 for any 
item was indicative of the “Presence of SOM” (category 1). In contrast, OAG scores of 1 and 2 indicated 
“Absence of SOM” (category 0). 
The work team was composed of calibrated examiners (Kappa index value of 0.74 - satisfactory 
agreement) and trained notetakers. The oral mucosal examinations were carried out at baseline (at diagnosis or 
prior to the start of treatment) and in the 2nd, 5th and 10th weeks of antineoplastic treatment. These 
timepoints were based on the estimated time for the onset of oral mucosal alterations in patients undergoing 
cancer therapy, which is up to two and a half months (10 weeks) [17]. 
 
Definiton of Variables 
The response (dependent) variable “occurrence of severe oral mucositis” was categorized into “absent” 
(0) and “present” (1). The following explanatory variables were selected: age, sex, skin color, type of tumor, use 
of methotrexate, class of chemotherapeutic drugs used, type of drug in each class, leukocyte count, platelet 
count, and blood creatinine level. The variable age was categorized into “up to 10 years old” and “10 years or 
older” because study participants had a median age of 10 years. 
Four classes of chemotherapeutic drugs were considered, according to the classification of the 
National Health Surveillance Agency, namely: alkylating agents, antimetabolites, natural products and 
miscellaneous. The present study focused on the class of antimetabolites, particularly methotrexate (MTX), 
since previous studies have shown that patients under chemotherapy regimen with antimetabolites are more 
likely to develop SOM [7,8]. MTX is one of the most widely used chemotherapeutic drugs, despite presenting 
stomatotoxicity and being frequently related to the occurrence of SOM [18]. 
The same reference values adopted by the HNL for leukocytes, platelets, and creatinine in pediatric 
cancer patients were also considered here in the analysis of hematological and biochemical parameters. The 
values fit one of three categories: 1: below the normal range; 2: within the normal range; 3: above the normal 
range. The leukocyte count was categorized into 1: less than 3,400 / mm3; 2: between 3,400 to 9,500 / mm3; or 
3: greater than 9,500 / mm3. The platelet count was categorized into 1: less than 150,000 / mm³; 2: between 
150,000 and 450,000 / mm³; or 3: greater than 450,000 / mm³. Lastly, the creatinine level was categorized into 
1: less than 0.4 mg / dl; 2: between 0.4 and 1.3 mg / dl; or 3: greater than 1.3 mg / dl. 
 
Data Analysis 
The data were categorized, entered into a database, and analyzed descriptively by calculating the 
measures of central tendency and dispersion, as well as absolute and relative frequencies. Pearson's chi-square 
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test was used to check for associations between the explanatory variables (age, hematological tumor diagnosis, 
use of antimetabolites, use of MTX, leukocyte count, platelet count and blood creatinine level) and the 
dependent variable “occurrence of SOM” (present or absent). The data were analyzed in SPSS version 21.0. 
program, considering a 5% significance level. 
 
Ethical Considerations 
This study was previously approved by the Research Ethics Committee of the Center for Health 
Sciences at the Federal University of Paraíba, under Protocol No. 046/17 (CAAE 64249317.3.0000.5188). 
 
Results 
In the period from November 2016 to June 2019, 85 children and adolescents assisted by the dental 
care team at the outpatient clinic and infirmary of the HNL Pediatric Oncology Sector were included in the 
study. Table 1 shows the sociodemographic characteristics of study participants. Most patients were males 
(50.6%) and self-reported as mixed race (51.8%). The participants' mean age was 9.5 (± 5.4) years, with a 
median age of 10 years (minimum of 0 and a maximum of 19 years). Most of them were not from the state 
capital and lived in other cities across the state of Paraíba (72.9%). 
 
Table 1. Sociodemographic characteristics of pediatric cancer patients. 
Variables N % 
Sex   
Female 42 49.4 
Male 43 50.6 
Age (9.5 ± 5.4 Years)   
< 10 Years 44 51.8 
≥ 10 Years 41 48.2 
Self-Reported Skin Color   
Mixed Race 44 51.8 
White 35 41.2 
Black 3 3.5 
Indigenous 2 2.3 
Not Stated 1 1.2 
City of Residence   
João Pessoa 18 21.2 
Other Cities in the State of Paraíba 64 72.9 
Cities in Other States 3 5.9 
 
The clinical and epidemiological data of the pediatric patients can be found in Table 2. There was a 
higher prevalence of hematological neoplasms, of which Acute Lymphoid Leukemia (ALL) was the most 
common underlying disease (35.3%). Most patients were submitted to exclusive chemotherapy (79.8%). 
Natural products were the most common class of chemotherapeutic drugs administered in the 1st 
week of antineoplastic treatment (94.8%), especially vincristine, doxorubicin and daunorubicin. These drugs 
were used alone or in combination with other classes of drugs. During the follow-up period, natural products 
remained as the most frequently administered class, usually in combination with chemotherapeutic drugs from 
other classes such as MTX (antimetabolites) and cyclophosphamide (alkylants). 
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Table 2. Clinical and epidemiological profile of pediatric cancer patients. 
Type of Tumor / Underlying Disease N % 
Hematological Tumor   
Acute Lymphoblastic Leukemia 30 35.3 
Acute Myeloid Leukemia 11 13.0 
Non-Hodgkin's Lymphoma 9 10.6 
Hodgkin's Lymphoma 7 8.2 
Total 57 67.1 
Solid Tumor   
Osteosarcoma 8 9.4 
Wilms Tumor 4 4.7 
Rhabdomyosarcoma 4 4.7 
Neuroblastoma 3 3.5 
Testicular Tumor 3 3.5 
Central Nervous System Tumor 2 2.3 
Breast Cancer 1 1.2 
Melanoma 1 1.2 
Ovarian Tumor 1 1.2 
Ewing's Sarcoma 1 1.2 
Total 28 32.9 
Antineoplastic Therapy 
  
Exclusive Chemotherapy 67 79.8 
Chemotherapy and Surgery 11 13.1 
Chemotherapy and Radiotherapy 7 7.1 
Class of Chemotherapeutic Drug Administered in the 1st Week of Treatment* 
  
Natural Products 79 94.8 
Antimetabolites 27 32.4 
Alkylants 15 17.7 
Miscellaneous 9 10.8 
*Patients were administered chemotherapeutic drugs of more than one class. 
 
The occurrence and severity of OM were assessed by the modified OAG. Table 3 shows that OM was 
most frequent (60%) 2 weeks after the start of treatment and that 32.3% of the patients developed SOM in the 
2nd week. 
 
Table 3. The occurrence and severity of oral mucositis in pediatric cancer patients, per week of 
antineoplastic treatment. 
Variables Presence Absence Total 
 N % N % N % 
Oral Mucositis       
2nd Week 41 60.0 27 40.0 68 100.0 
5th Week 20 40.9 29 59.1 49 100.0 
10th Week 16 43.2 21 56.8 37 100.0 
Severe Oral Mucositis       
2nd Week 22 32.3 46 67.7 68 100.0 
5th Week 17 34.7 32 65.3 49 100.0 
10th Week 11 29.7 26 70.3 37 100.0 
 
Table 4 describes the absolute and percent frequencies of SOM for each study variable per week of 
antineoplastic treatment. OM was most frequently observed in patients younger than 10 years (42.9%) in the 
10th week of antineoplastic treatment. In the 2nd week of follow-up, the occurrence of SOM was greater in 
patients with hematological tumors (31.4%) compared to those with solid tumors. SOM cases were more 
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frequent among patients undergoing chemotherapy with antimetabolites after the 5th week (31.6%) and 10th 
week (43.5%) of treatment. In all follow-up timepoints, there was a higher predominance of SOM in patients 
not treated with MTX, although such differences were not statistically significant. 
As for hematological and biochemical parameters, our study showed that leukopenic patients had a 
higher frequency of SOM (43.8%) in the 10th week of antineoplastic treatment. SOM cases prevailed in 
thrombocytopenic children and adolescents in the 2nd week (30.4%) and 10th week (50.0%) of treatment. 
Patients with a creatinine level within the range of 0.4 - 1.3 mg / dl had a higher incidence of SOM in the 2nd 
week (23.9%) and 5th week (31.0%) of treatment. Overall, there was no relationship between any of the 
hematological and biochemical parameters and the occurrence of SOM throughout the duration of treatment. 
 
Discussion 
HNL is the reference center for cancer treatment in the state of Paraíba, northeastern Brazil. Hence, 
the results presented herein describe the state-wide epidemiological profile of pediatric cancer patients [13].  
Our findings showed that most children and adolescents with cancer were males, which is consistent 
with other reports in northern Brazil (64.4% prevalence of males) [19] and in Hong Kong (69 children, 64% 
prevalence of males) [20]. 
The HNL Pediatric Oncology Sector admits patients aged 0 to 19 years. According to their medical 
records, the mean age of the patients in our study was 9.5 years (± 5.4 years) and a median age of 10 years, 
which is also in line with the Hong Kong study [20]. Here, the highest prevalence of cancer was observed in 
patients aged up to 10 years, corroborating the findings of a study carried out in oncology services in the 
Brazilian states of Rio Grande do Sul and Piauí [19]. 
Self-reported mixed race was predominant (51.8%) in our study sample. This percentage is comparable 
to that of a study with 689 children admitted to a referral hospital in Teresina, PI, Brazil, which showed that 
58.0% of the pediatric cancer patients were self-reported mixed-race [21]. Intriguingly, the 2010 demographic 
census of the Brazilian Institute of Geography and Statistics indicated that the Brazilian population aged 0 to 
19 years is predominantly white [22]. A possible explanation for the predominance of mixed-race children and 
adolescents, in both studies, may be that such a population is more frequently assisted by the Brazilian 
Healthcare System (BHS). A previous study found that black and mixed-race individuals, with less schooling 
and lower family income per capita, were more likely to use the BHS. Hence, groups from poorer 
socioeconomic backgrounds comprise most of the BHS users [23]. 
In our study, most participants were reportedly not from the state capital (72.9%), João Pessoa, and a 
small percentage of them had come from other states of Brazil (3.5%) for treatment. Access to healthcare 
services is a critical aspect of cancer care, particularly in terms of geographic accessibility, which remains a 
major difficulty faced by healthcare users in need of antineoplastic treatment. Due to regional accessibility 
issues, some patients and family members or caregivers cannot always travel to the places where healthcare 
facilities are located [24]. This is also seen in other countries, where healthcare services for the diagnosis and 
treatment of childhood cancer are predominantly restricted to a few tertiary care centers located in major 
cities. This configuration does not favor an early diagnosis of childhood cancer and contributes to an increased 
risk of death [25, 26]. In a previous study, pediatric cancer patients from the state of Paraíba and / or their 
family members or caregivers reported they were provided with transportation to/from the HNL Pediatric 
Oncology Sector by the municipal administration [27]. 
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Table 4. Factors associated with the occurrence of severe oral mucositis in pediatric cancer patients, per week of antineoplastic treatment. 
 Occurrence of Severe Oral Mucositis Per Week of Treatment Variables 2nd Week 5th Week 10th Week 
 Present Absent Present Absent Present Absent 
 N % N % N % N % N % N % 
Age             
< 10 Years 9 27.3 24 72.7 6 31.6 13 68.4 6 42.9 8 57.1 
≥ 10 Years 13 37.1 22 62.9 11 36.7 19 63.3 5 21.8 18 78.2 
p-value 0.385 0.715 0.173 
Hematological Tumor             
Yes 16 31.4 35 68.6 14 37.9 23 62.1 9 32.2 19 67.8 
No 6 35.3 11 64.7 3 25.0 9 75.0 2 22.3 7 77.7 
p-value 0.765 0.417 0.571 
Use of Antimetabolites(a)             
Yes 6 27.3 16 72.7 6 31.6 13 68.4 4 43.5 13 56.5 
No 11 33.3 22 66.7 6 26.1 17 73.9 6 37.5 10 62.5 
p-value 0.581 0.695 0.383 
Use of Methotrexate(a)             
Yes 3 17.7 14 82.3 3 25.0 9 75.0 2 18.2 9 81.8 
No 14 36.9 24 63.1 9 30.0 21 70.0 8 36.4 14 63.6 
p-value 0.155 0.746 0.284 
Leukocyte Count(b)             
< 3,400 / mm³ 10 32.3 21 67.7 4 25.0 12 75.0 7 43.8 9 56.2 
3,400 – 9,500 / mm³ 6 33.3 12 66.7 8 44.4 10 55.6 2 13.3 13 86.7 
> 9,500 / mm³ 2  15.4 11 84.6 3 25.0 9 75.0 1 25.0 3 75.0 
p-value 0.474 0.390 0.171 
Platelet Count(c)             
< 150,000 / mm³ 7 30.4 16 69.6 3 27.3 08 72.7 6 50.0 6 50.0 
150,000 – 450,000 / mm³ 10 30.3 23 69.7 9 32.1 19 67.9 4 21.1 15 78.9 
> 450.000 / mm³ 1 16.7 5 83.3 2 33.3 4 66.7 0 0.0 4 100.0 
p-value 0.781 0.950 0.090 
Blood Creatinine Level(d)             
< 0.4 mg / dl 7 41.2 10 58.8 5 38.5 8 61.5 4 44.4 5 55.6 
0.4 – 1.3 mg / dl 10 23.9 32 76.2 9 31.0 20 69.0 5 20.8 19 79.2 
> 1.3 mg / dl 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 
p-value 0.182 0.637 0.175 
(a)Loss of information in the 2nd week (13 patients), 5th week (7 patients) and 10th week (3 patients); (b)Loss of information in the 2nd week (6 patients), 5th week (5 patients) and 10th week (2 patients); (c)Loss of 
information in the 2nd week (6 patients), 5th week (4 patients) and 10th week (2 patients); (d)Loss of information in the 2nd week (9 patients), 5th week (5 patients) and 10th week (4 patients). 
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Our findings indicated a higher prevalence of hematological neoplasms (66.7% of cases) in the study 
sample. This is consistent with what was found in Hong Kong, where hematological neoplasms were more 
prevalent than solid tumors [20]. Evidence has shown that while hematological tumors account for only 6.2% 
of neoplasms in all age groups, they are the most prevalent type of tumor during childhood worldwide [28, 
29]. 
Acute Lymphoblastic Leukemia (ALL) was the most frequent neoplasm in our study sample, affecting 
30 children and adolescents (35.3%). These findings corroborate those of the literature, which shows that ALL 
is more prevalent in children aged 0 to 14 years [30]. The onset of ALL in patients within this age range can 
be explained by an impaired development of the immune system, which renders the patient more susceptible to 
severe infectious conditions [31]. 
Other neoplasms observed in the sample included Acute Myeloid Leukemia (AML) (13%), Hodgkin's 
Lymphoma (8.2%) and Non-Hodgkin's Lymphoma (10.6%). AML cases account for approximately 18% of 
leukemia cases worldwide and are more prevalent in the neonatal period. Hodgkin's Lymphoma corresponds to 
5% of childhood neoplasms, with a higher prevalence in individuals under 14 years of age. Studies have shown 
that Hodgkin's and Non-Hodgkin's Lymphomas are associated with immunodeficiency and infectious process 
caused by the Epstein-Barr virus and cytomegalovirus [32]. 
Our study and another one carried out in the state of Paraná [33] revealed that chemotherapy was the 
most widely used therapeutic approach among pediatric cancer patients, either alone or in combination with 
other treatments. Chemotherapy, together with radiotherapy and surgery are the main modalities currently 
available to treat childhood cancer [34]. In our study sample, all patients undergoing radiotherapy were also 
submitted to chemotherapy. The literature points out that radiotherapy should be used with caution and that it 
is being gradually less indicated in the treatment of children and adolescents due to its late side effects [35]. 
The antineoplastic treatment, particularly chemotherapy, has been implicated in the onset of oral 
manifestations in children and adolescents with cancer [36]. For instance, the risk of developing OM is 
increased during ALL treatment with antimetabolites such as MTX (which impairs cell metabolism, including 
cell division) or with pro- and anti-inflammatory therapies based on cytokines or pro-LL37 [36]. As shown in 
a previous study, antimetabolites have been widely prescribed in the HNL reference center. The representative 
drug of this class is MTX, a chemotherapeutic agent frequently administered to pediatric patients with cancer, 
especially to non-metastatic and older patients, due to their lower sensitivity to adverse effects [7]. 
Our study showed that 32.4% of patients were administered antimetabolites in the 1st week of 
antineoplastic treatment. Choosing the chemotherapeutic drug class in the early stages of treatment is critical, 
as the development of OM is known to be most significant in the first ten days of cancer therapy [37]. Herein, 
the occurrence of OM and SOM ranged from 40.9 to 60% and from 29.7 to 32.3%, respectively. The first 
symptoms of OM begin in approximately 10 days of drug administration, with lesions lasting 6 days on 
average [37]. This explains the higher incidence of OM and SOM observed in sample subjects in the 2nd week 
of treatment. 
The modified OAG considers oral conditions that are not commonly addressed in other assessment 
tools [17]. For example, the presence of SOM is not only indicated by ulcerative lesions, but also by changes 
in the voice, absence of saliva and dryness of the lip vermilion. This may explain the higher incidence of OM 
and SOM observed here compared with that of studies using other tools such as the WHO scale [4,41]. 
The onset of SOM has been associated with external factors and patient characteristics. In our study, 
there was no association between the occurrence of SOM and the participant’s age. However, studies have 
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shown that younger patients are more likely to experience adverse effects of chemotherapy, such as OM 
[17,38]. In line with our findings, a previous study carried out in the HNL reference center showed no 
significant association between SOM occurrence and the participant’s age. However, the authors pointed out 
that patients older than 10 years had lesions lasting 1.4 times longer than younger patients [7]. The influence 
of age on the severity of mucositis is reasoned to be a result of the difference in tissue maturity, given that 
younger individuals have intense cell turnover, which contributes to greater drug susceptibility and faster 
regeneration [5]. Here, the small number of patients evaluated throughout the follow-up period and the 
sample losses may have not allowed detecting significant differences between the occurrence of SOM and the 
participant’s age. 
Another study carried out in the HNL reference center demonstrated that children undergoing 
chemotherapy for hematological neoplasms developed OM more frequently [11]. Patients with hematological 
neoplasms were shown to have a seven-fold increased risk of presenting OM lesions when compared to those 
with solid or central nervous system tumors [6]. Despite this, in our study, there was no association between 
the occurrence of SOM and the type of tumor throughout the whole follow-up period. 
Individuals with hematological tumors are most often treated with antimetabolites, which are the 
drugs most stomatotoxic to the oral mucosa [18]. The modified OAG data revealed that the chemotherapeutic 
regimen affected patient swallowing as well as the labial and jugal mucosa, palate, and gingiva, especially in 
patients with hematological tumors [16]. However, the chemotherapeutic drugs of choice in the treatment of 
pediatric cancer are not equally stomatotoxic. MTX and 5-fluorouracil, both antimetabolites, are the drugs 
most reported to cause alterations in the oral mucosa [8,18]. Patients whose therapeutic regimens do not 
include MTX tend to have a lower occurrence of SOM [7]. Unexpectedly, this study found no association 
between the use of MTX and the occurrence of SOM during ten weeks of treatment. Preventive oral care 
measures are known to mitigate the occurrence and progression of OM even in patients being administered 
high drug doses [6], which could partially explain the lack of association observed herein.  
The implementation of a systemic prophylactic protocol for patients undergoing chemotherapy could 
mitigate drug-related adverse effects. The HNL protocol includes the use of cytoprotectors, for example, 
amifostine, which provides less liver, cardiac, pulmonary, and oral mucosal damage [7]. Of note, we did not 
test any associations between the type of tumor (hematological or solid) and the outcome of interest (presence 
or absence of OM) because the protocols were different and were not examined here. This could also explain 
the lack of association between the use of antimetabolites, such as MTX, and the occurrence of SOM. 
Following the cancer diagnosis, children should be ideally assisted by a dentist working in 
collaboration with the pediatric oncology team, so that dental care preferably precedes the antineoplastic 
treatment to prevent complications and delays [29]. A study carried out in the HNL Pediatric Oncology 
Sector surveyed patient access to the hospital and their satisfaction with dental care services. The authors 
reported that most patients did not experience difficulties when seeking dental care in healthcare facilities close 
to their households [27]. 
While there is evidence suggesting that chemotherapy may affect blood cells and thereby cause 
leukopenia and thrombocytopenia [39,40], our data showed no association between the patients’ hematological 
and biochemical parameters and the occurrence of SOM at any timepoint. Studies show that low leukocyte and 
platelet counts increase the risk of developing mucositis. This may be because, once the neutrophil count is 
reduced, the host immune response becomes less efficient to adequately manage the cytotoxic effects of the 
chemotherapeutic drug against the oral mucosa [39,40]. Neutropenic patients have a 7.5-fold greater risk of 
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developing OM [6], especially if their leukocyte count is below 9,500 / mm³ [11]. SOM causes loss of tissue 
integrity, thus increasing the patient’s risk of bacterial infection, sepsis, and death [41]. 
The association between platelet count and the occurrence of SOM remains conflicting. While patients 
with thrombocytopenia are expected to be more likely to develop SOM, our findings showed no significant 
association between these variables. On the other hand, a study carried out in the HNL reference center 
reported that high platelet count may be a risk factor for developing SOM. The authors further reported that 
the high platelet count in participating patients resulted from a transfusion of platelet concentrate and that 
such pediatric patients were immunocompromised [11]. 
In our study, creatinine levels were not related to the occurrence of SOM. Creatinine is a blood-
circulating byproduct directly involved with glomerular filtration and that serves as a renal function marker. 
Several chemotherapeutic drugs (e.g., cisplatin, epirubicin, cyclophosphamide, paclitaxel and melphalan) are 
nephrotoxic and have been shown to alter blood creatinine and urea levels [42]. Thus, the use of drugs that 
may alter renal function contributes to drug depuration issues and increased body toxicity, which may also 
favor the development of SOM [43]. 
Childhood cancer is a rare condition when compared to the prevalence of neoplasms in adults. 
Therefore, cancer research in children and adolescents involves difficulties in terms of patient randomization. 
The sampling process in our study was defined for convenience, and the inclusion criteria consisted of 
admission to the HNL Pediatric Oncology Sector and consent participation. Another limitation of the present 
study was the loss of follow-up due to continuity of treatment in other locations, home stay, or due to death. 
However, while the loss of follow-up may compromise the internal validity and conclusions of our study, this is 
a frequent shortcoming in pediatric cancer research. 
Study participants had heterogeneous characteristics and were submitted to different therapeutic 
protocols based on their underlying diseases, which could render the extrapolation of results potentially biased. 
However, grouping children and adolescents into two groups (solid tumors and hematological neoplasms) was 
an effective strategy used in our study to overcome this limitation. Moreover, there are other explanatory 
variables, which were not included, that may be associated with the occurrence of OM, such as genetic factors, 
oral hygiene condition, and the dose of chemotherapeutic drugs. 
Taken altogether, the findings presented herein may contribute to a better understanding of the 
factors associated with the occurrence and severity of OM, particularly of SOM, in pediatric cancer patients. 
Our results reinforce the need for clinical conduct of oral health surveillance, especially in the 2nd week of 
antineoplastic treatment, when children and adolescents are more likely to develop this comorbidity. 
 
Conclusion 
The occurrence of oral mucositis in pediatric cancer patients was significant, especially in the 2nd 
week of antineoplastic treatment. Severe oral mucositis was more prevalent in the 5th week of treatment and 
was not associated with any of the study variables. 
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